Products
Obertamig Biosimilar Bispecific Antibody (CD3 × HLA-G) for Research
Cat No.: GMP-Bios-INN-1306
Anti-CD3E therapeutic antibody (Pre-made Obertamig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Obertamig (development code JNJ-78306358) is a bispecific antibody targeting CD3 and HLA. It is developed by Janssen Research & Development and Zymeworks. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1306-1mg | 1mg | |
| GMP-Bios-INN-1306-10mg | 10mg | |
| GMP-Bios-INN-1306-100mg | 100mg | |
| GMP-Bios-INN-1306-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Obertamig biosimilar, Bispecific Mixed mAb and scFv, Anti-CD3E;HLA-G Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Obertamig |
| Target | CD3E;HLA-G |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Janssen Research & Development;Zymeworks |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
